New weekly Weight-Loss shot shows promise in Mid-Stage trial

NCT ID NCT06712836

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called MET097, given as a weekly injection, to help adults with obesity or overweight lose weight. 239 participants received either MET097 or a placebo for 28 weeks. The main goal was to see how much weight people lost compared to those on placebo. Results are now available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MET097 (a long-acting GLP-1 analog)
What this could lead to: If successful, this could lead to a new once-weekly injection for significant weight loss in people with obesity or overweight.
What could go wrong: This is a Phase 2b trial with 239 participants, so results are still early. The drug may cause side effects or not work better than placebo in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Anaheim Clinical Trials, LLC

Anaheim, California, 92801, United States
Research Centers of America

Hollywood, Florida, 92801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.